Cited by 77Nuclear Structure and FunctionCardiomyopathy and Myosin StudiesCongenital heart defects research

BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C–deficient mice

Open access
Auguste, Gaelle, Rouhi, Leila, Matkovich, Scot J., Coarfa, Cristian, Robertson, Matthew J., Czernuszewicz, Grazyna, Gurha, Priyatansh, Marian, Ali J.·2020·Journal of Clinical Investigation

Abstract

Mutation in the LMNA gene, encoding lamin A/C, causes a diverse group of diseases called laminopathies. Cardiac involvement is the major cause of death and manifests as dilated cardiomyopathy, heart failure, arrhythmias, and sudden death. There is no specific therapy for LMNA-associated cardiomyopathy. We report that deletion of Lmna in cardiomyocytes in mice leads to severe cardiac dysfunction, conduction defect, ventricular arrhythmias, fibrosis, apoptosis, and premature death within 4 weeks. The phenotype is similar to LMNA-associated cardiomyopathy in humans. RNA sequencing, performed before the onset of cardiac dysfunction, led to identification of 2338 differentially expressed genes (DEGs) in Lmna-deleted cardiomyocytes. DEGs predicted activation of bromodomain-containing protein 4 (BRD4), a regulator of chromatin-associated proteins and transcription factors, which was confirmed by complementary approaches, including chromatin immunoprecipitation sequencing. Daily injection of JQ1, a specific BET bromodomain inhibitor, partially reversed the DEGs, including those encoding secretome; improved cardiac function; abrogated cardiac arrhythmias, fibrosis, and apoptosis; and prolonged the median survival time 2-fold in the myocyte-specific Lmna-deleted mice. The findings highlight the important role of LMNA in cardiomyocytes and identify BET bromodomain inhibition as a potential therapeutic target in LMNA-associated cardiomyopathy, for which there is no specific effective therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci135922

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In mice with pressure-overload heart failure, BET inhibition with JQ1 strongly protected left ventricular ejection fraction.

    “BET inhibition exerted a strong protective effect on left ventricular ejection fraction (Fig. 1B)4,6-10.”

    From Chromatin remodelling drives immune cell–fibroblast communication in heart failure (2024) · cites this paper as [10]

    The 'Effects of JQ1 on cardiac function' section reports improved left ventricular function after JQ1 treatment, but the mice had myocyte-specific lamin A/C deficiency, not pressure-overload heart failure. It reports improved fractional shortening (LVFS), not a measured protective effect on ejection fraction. The paper mentions beneficial effects in pressure-overload models only when discussing previous studies; page numbers are unavailable in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [41]41. Stratton MS, Haldar SM, McKinsey TA. BRD4 inhi- bition for the treatment of pathological organ fibro- sis. F1000Res. 2017;6:F1000 Faculty Rev-1015.

Cited by

Sorted by citations

Authors
Auguste, G., Rouhi, L., Matkovich, S. J., Coarfa, C., Robertson, M. J., Czernuszewicz, G., Gurha, P., & Marian, A. J.
Affiliations
  • Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
  • Washington University in St. Louis (US)
  • Baylor College of Medicine (US)
Corresponding author
Marian, Ali J.
Venue
Journal of Clinical Investigation
Published
2020-08-10
Volume
130
Issue
9
Pages
4740-4758
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3031596611
Cited by
77
References
68
Citations by year
2026: 9 · 2025: 14 · 2024: 16 · 2023: 12 · 2022: 10 · 2021: 13 · 2020: 3
FWCI
3.08
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders
  • National Institutes of Health, Fondation Leducq (NHLBI,R01 HL088498,1R01HL132401,14 CVD 03,R21 AG060413)
  • NIH Office of the Director (S10 OD018135, R01HL151737)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
Keywords
lamin A/C, laminopathies, BRD4, BET bromodomain inhibition, JQ1, cardiomyocytes, cardiac dysfunction, ventricular arrhythmias, myocardial fibrosis, cardiomyocyte apoptosis, cardiac conduction disorders, secretome, differentially expressed genes, therapeutic target
MeSH terms
Bromodomain Containing Proteins, Animals, Azepines, Cardiomyopathy, Dilated, Gene Expression Regulation, Nuclear Proteins, Transcription Factors, Triazoles, Mice, Knockout, Myocytes, Cardiac, Lamin Type A, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review